Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goel, A.
Right arrow Articles by Boland, C. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goel, A.
Right arrow Articles by Boland, C. R.
[Cancer Research 64, 3014-3021, May 1, 2004]
© 2004 American Association for Cancer Research


Regular Articles

Frequent Inactivation of PTEN by Promoter Hypermethylation in Microsatellite Instability-High Sporadic Colorectal Cancers

Ajay Goel1, Christian N. Arnold1,3, Donna Niedzwiecki2, John M. Carethers1,3, Jeannette M. Dowell2, Linda Wasserman1, Carolyn Compton4, Robert J. Mayer5, Monica M. Bertagnolli6 and C. Richard Boland1,3

1 Department of Medicine and Comprehensive Cancer Center, University of California San Diego, La Jolla, California; 2 Cancer and Leukemia Group B Statistical Center, Duke University, Durham, North Carolina; 3 San Diego Veteran Affairs Medical Center, La Jolla, California; 4 Department of Pathology, McGill University, Montreal, Quebec, Canada; 5 Department of Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts; and 6 Brigham and Women’s Hospital, Boston, Massachusetts

Loss of PTEN tumor suppressor function is observed in tumors of breast, prostate, thyroid, and endometrial origin. Allelic losses in the proximity of the PTEN locus (10q23) also occur in sporadic colorectal cancers (CRCs), but biallelic inactivation of this site has not been frequently demonstrated. We hypothesized that alternative mechanisms of PTEN allelic inactivation, such as promoter hypermethylation, might be operative in CRC and that PTEN inactivation may be related to recognized forms of genomic instability. We characterized a cohort of 273 sporadic CRCs by determining their microsatellite instability (MSI) status. Of these, 146 cancers were examined for PTEN promoter methylation by methylation-specific PCR. Mutations at the poly(A)6 repeat sequences in PTEN exons 7 and 8 and deletions at the 10q23 locus were also identified using microsatellite analysis. The presence of PTEN protein was determined by immunostaining, and the results were correlated with the promoter methylation status. We observed that PTEN promoter hypermethylation was a frequent occurrence in MSI-high (MSI-H) tumors (19.1% of MSI-H versus 2.2% of MSI-low/microsatellite stable tumors; P = 0.002). A PTEN mutation or a deletion event was present in 60% of the tumors with promoter region hypermethylation. Hypermethylation of the PTEN promoter correlated significantly with either decreased or complete loss of PTEN protein expression (P = 0.004). This is the first demonstration of PTEN inactivation as a result of promoter hypermethylation in MSI-H sporadic CRCs. These data suggest that this silencing mechanism plays a major role in PTEN inactivation and, in colon cancer, may be more important than either allelic losses or inactivating mutations. The significant correlation of PTEN hypermethylation with MSI-H tumors further suggests that PTEN is an additional important "target" of methylation along with the hMLH1 gene in the evolution of MSI-H CRCs and also confers the "second hit" in the biallelic inactivation mechanism for some proportion of tumors.




This article has been cited by other articles:


Home page
GlycobiologyHome page
H.-J. Choi, T.-W. Chung, S.-J. Kim, S.-Y. Cho, Y.-S. Lee, Y.-C. Lee, J.-H. Ko, and C.-H. Kim
The AP-2{alpha} transcription factor is required for the ganglioside GM3-stimulated transcriptional regulation of a PTEN gene
Glycobiology, May 1, 2008; 18(5): 395 - 407.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Jhawer, S. Goel, A. J. Wilson, C. Montagna, Y.-H. Ling, D.-S. Byun, S. Nasser, D. Arango, J. Shin, L. Klampfer, et al.
PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab
Cancer Res., March 15, 2008; 68(6): 1953 - 1961.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. Y.C. Chow, K. T. Quach, B. L. Cabrera, J. A. Cabral, S. E. Beck, and J. M. Carethers
RAS/ERK modulates TGF{beta}-regulated PTEN expression in human pancreatic adenocarcinoma cells
Carcinogenesis, November 1, 2007; 28(11): 2321 - 2327.
[Abstract] [Full Text] [PDF]


Home page
Neuro OncolHome page
J. K. Wiencke, S. Zheng, N. Jelluma, T. Tihan, S. Vandenberg, T. Tamguney, R. Baumber, R. Parsons, K. R. Lamborn, M. S. Berger, et al.
Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma
Neuro-oncol, July 1, 2007; 9(3): 271 - 279.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
S. Y. Kim and W. C. Hahn
Cancer genomics: integrating form and function
Carcinogenesis, July 1, 2007; 28(7): 1387 - 1392.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. W. Watters and C. J. Roberts
Developing gene expression signatures of pathway deregulation in tumors.
Mol. Cancer Ther., October 1, 2006; 5(10): 2444 - 2449.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. M. Goldberg, D. Niedzwiecki, M. Bertagnolli, A. W. Blackstock, J. E. Tepper, and R. J. Mayer
Cancer and leukemia group B gastrointestinal cancer committee.
Clin. Cancer Res., June 1, 2006; 12(11): 3589s - 3595s.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Compton
The cancer and leukemia group B pathology committee at 50.
Clin. Cancer Res., June 1, 2006; 12(11): 3617s - 3621s.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. Hartmann, B. Digon-Sontgerath, A. Koch, A. Waha, E. Endl, I. Dani, D. Denkhaus, C. G. Goodyer, N. Sorensen, O. D. Wiestler, et al.
Phosphatidylinositol 3'-Kinase/AKT Signaling Is Activated in Medulloblastoma Cell Proliferation and Is Associated with Reduced Expression of PTEN.
Clin. Cancer Res., May 15, 2006; 12(10): 3019 - 3027.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
S. Xi, K. F. Dyer, M. Kimak, Q. Zhang, W. E. Gooding, J. R. Chaillet, R. L. Chai, R. E. Ferrell, B. Zamboni, J. Hunt, et al.
Decreased STAT1 Expression by Promoter Methylation in Squamous Cell Carcinogenesis
J Natl Cancer Inst, February 1, 2006; 98(3): 181 - 189.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2004 by the American Association for Cancer Research.